Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...